Skip to main content
Monday, November 16, 2026Nov 16

New HIV vaccine trial to start in South Africa

FILE -- In this Dec. 1, 2014 file photo a man makes a call on a mobile phone as he passes World AIDS Day banners on the perimeter of an office building in Sandton, Johannesburg, South Africa.  A new vaccine against HIV, called HVTN 702, is to be tested in South Africa, it is announced Sunday Nov. 27, 2016, and scientists aims to enroll 5,400 sexually active men and women for the clinical trial. (AP Photo/Denis Farrell, File)
FILE -- In this Dec. 1, 2014 file photo a man makes a call on a mobile phone as he passes World AIDS Day banners on the perimeter of an office building in Sandton, Johannesburg, South Africa. A new vaccine against HIV, called HVTN 702, is to be tested in South Africa, it is announced Sunday Nov. 27, 2016, and scientists aims to enroll 5,400 sexually active men and women for the clinical trial. (AP Photo/Denis Farrell, File)

JOHANNESBURG (AP) – A new vaccine against HIV, to be tested in a trial to be launched in South Africa Wednesday, could be “the final nail in the coffin” for the disease if it is successful, scientists say.

The study, called HVTN 702, aims to enroll 5,400 sexually active men and women aged between 18 and 35 at 15 sites across South Africa.

It will be the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people a day are infected with HIV.

“If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV,” Anthony Fauci, director of the U.S. government’s National Institute of Allergy and Infectious Diseases (NIAID), said in a statement released ahead of the trial.

“Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa,” he said.